Super Fund Lookup is the ATO's external register of Self-Managed Super Funds' (SMSF) current compliance statuses. Employers can utilise this service to determine whether employer contributions qualify as superannuation guarantee payments.
Valsartan and hydrochlorothiazide is manufactured by Novartis Pharmaceuticals. Valsartan and hydrochlorothiazide is a combination of two medicines -- valsartan and hydrochlorothiazide. Valsartan is a newer type of blood pressure medicine known as an angiotensin II receptor blocker, or ARB for short.
The primary circulating metabolite, 4-OH-valsartan, is pharmacologically inactive and produced CYP2C9. 4-OH-valsartan accounts for approximately 9% of the circulating dose of valsartan. Although valsartan is metabolized by CYP2C9, CYP-mediated drug-drug interactions between valsartan and other drugs is unlikely.